<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02197520</url>
  </required_header>
  <id_info>
    <org_study_id>15407</org_study_id>
    <secondary_id>I2R-MC-BIDV</secondary_id>
    <nct_id>NCT02197520</nct_id>
  </id_info>
  <brief_title>A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics</brief_title>
  <official_title>The Effect of Treatment With Basal Insulin Peglispro or Insulin Glargine on Insulin Sensitivity and the Effect of Prandial Insulin Lispro in Patients With Type 2 Diabetes Mellitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will look into insulin sensitivity (how the body responds to insulin) and effects
      of meals on type 2 diabetics comparing insulin peglispro to insulin glargine. The study has
      two treatment periods, each of which will last about four weeks. One drug (insulin peglispro
      or insulin glargine) will be administered in each period. Participants will receive both
      drugs during the study. Participants may remain on stable dose metformin, as prescribed by
      their personal physician.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2014</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacodynamics: Average Glucose Infusion Rate from Euglycemic 2-step Hyperinsulinemic Clamp (M-value)</measure>
    <time_frame>Day 33, last 30 minutes (final step) of euglycemic 2-step hyperinsulinemic clamp</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacodynamics: Plasma Glucose Area Under the Concentration Curve (AUC) Above Pre Meal Baseline for Insulin Lispro</measure>
    <time_frame>Predose through 5 hours postdose of insulin lispro on Days 30 through 32 of study insulin dosing.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) for Prandial Insulin Lispro</measure>
    <time_frame>Predose through 5 hours post insulin lispro dose on Day 29 of study insulin dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) for Acetaminophen</measure>
    <time_frame>Predose through 5 hours post acetaminophen dose on Day 29 of study insulin dosing</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Appetite and Satiety Ratings, as Measured Using Visual Analog Scale (VAS)</measure>
    <time_frame>Day 29, predose through 5 hours post breakfast</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics: Area Under the Concentration Curve (AUC) for Insulin Lispro During Clamp</measure>
    <time_frame>Day 33 during euglycemic 2-step hyperinsulinemic clamp</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Insulin Peglispro (with Insulin Lispro)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Insulin peglispro, a once daily subcutaneous injection at bedtime for 5 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Insulin Glargine (with Insulin Lispro)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Insulin glargine, a once daily subcutaneous injection at bedtime for 5 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Peglispro</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>Insulin Peglispro (with Insulin Lispro)</arm_group_label>
    <other_name>LY2605541</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Glargine</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>Insulin Glargine (with Insulin Lispro)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insulin Lispro</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>Insulin Peglispro (with Insulin Lispro)</arm_group_label>
    <arm_group_label>Insulin Glargine (with Insulin Lispro)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable glycated hemoglobin (HbA1c) less than (&lt;) 10.0 percent (%)

          -  Stable dose of either 0.2 to 1.5 units per kilogram per day (U/kg/day) basal insulin
             or a total daily insulin dose l&lt;2.0 units per kilogram (U/kg)

          -  C-peptide &lt;0.3 nanomole per liter (nmol/L)

          -  Stable body during the last 2 months

        Exclusion Criteria:

          -  Corrected QT interval (QTc) prolongation greater than (&gt;) 500 milliseconds (ms) or
             have any other abnormality in the 12 lead

          -  Abnormal blood pressure

          -  A history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine (apart from Type 1 Diabetes Mellitus (T1DM)),
             hematological, or neurological disorders capable of significantly altering the
             absorption, metabolism, or elimination of drugs; of constituting a risk when taking
             the study medication; or of interfering with the interpretation of data

          -  Currently treated with oral antidiabetic drugs (OADs) (excluding metformin and
             dipeptidyl peptidase-4 (DPP4) inhibitors), or glucagon-like peptide-1 (GLP-1) agonists
             or intend to use over-the counter or prescription medication, herbal medications, or
             nutritional supplements that affect PG or insulin sensitivity, impact on hypoglycemic
             awareness or promote weight loss within 4 weeks prior to randomization

          -  Fasting triglycerides (TGs) &gt;400 milligrams per deciliter (mg/dL) (4.52 millimoles per
             liter (mmol/L))

          -  Have used systemic or inhaled corticosteroids/glucocorticoid therapy (excluding
             topical, intra-articular, and intraocular preparations) within 4 weeks prior to
             randomization

          -  Currently receive insulin by pump or insulin degludec

          -  Poorly controlled diabetes or known to have poor awareness of hypoglycemia

          -  History of gastroparesis or gastrointestinal malabsorption

          -  Require treatment with any drug other than insulin to treat diabetes

          -  Previous history of proliferative retinopathy

          -  Excessive consumers of xanthines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Profil Institute for Clinical Research Inc</name>
      <address>
        <city>Chula Vista</city>
        <state>California</state>
        <zip>91911</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 21, 2014</study_first_submitted>
  <study_first_submitted_qc>July 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2014</study_first_posted>
  <last_update_submitted>June 23, 2015</last_update_submitted>
  <last_update_submitted_qc>June 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 25, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Insulin Glargine</mesh_term>
    <mesh_term>Insulin Lispro</mesh_term>
  </intervention_browse>
  <pending_results>
    <submitted>March 17, 2018</submitted>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

